These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25139352)

  • 1. Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.
    Castaman G; Fijnvandraat K
    Blood; 2014 Oct; 124(15):2333-6. PubMed ID: 25139352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.
    Castaman G; Eckhardt C; van Velzen A; Linari S; Fijnvandraat K
    Semin Thromb Hemost; 2016 Jul; 42(5):507-12. PubMed ID: 27148839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A.
    Stoof SC; Sanders YV; Petrij F; Cnossen MH; de Maat MP; Leebeek FW; Kruip MJ
    Thromb Haemost; 2013 Mar; 109(3):440-9. PubMed ID: 23348756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
    Eckhardt CL; van Velzen AS; Peters M; Astermark J; Brons PP; Castaman G; Cnossen MH; Dors N; Escuriola-Ettingshausen C; Hamulyak K; Hart DP; Hay CR; Haya S; van Heerde WL; Hermans C; Holmström M; Jimenez-Yuste V; Keenan RD; Klamroth R; Laros-van Gorkom BA; Leebeek FW; Liesner R; Mäkipernaa A; Male C; Mauser-Bunschoten E; Mazzucconi MG; McRae S; Meijer K; Mitchell M; Morfini M; Nijziel M; Oldenburg J; Peerlinck K; Petrini P; Platokouki H; Reitter-Pfoertner SE; Santagostino E; Schinco P; Smiers FJ; Siegmund B; Tagliaferri A; Yee TT; Kamphuisen PW; van der Bom JG; Fijnvandraat K;
    Blood; 2013 Sep; 122(11):1954-62. PubMed ID: 23926300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.
    Jacquemin M; Vantomme V; Buhot C; Lavend'homme R; Burny W; Demotte N; Chaux P; Peerlinck K; Vermylen J; Maillere B; van der Bruggen P; Saint-Remy JM
    Blood; 2003 Feb; 101(4):1351-8. PubMed ID: 12393451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.
    Hart DP
    Front Immunol; 2020; 11():1498. PubMed ID: 32849511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of previously untreated patient studies in understanding the development of FVIII inhibitors.
    Carcao M; Re W; Ewenstein B
    Haemophilia; 2016 Jan; 22(1):22-31. PubMed ID: 26315604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
    Kallas A; Talpsep T
    Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia A in the third millennium.
    Franchini M; Mannucci PM
    Blood Rev; 2013 Jul; 27(4):179-84. PubMed ID: 23815950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
    Dasgupta S; Navarrete AM; Delignat S; Wootla B; Andre S; Nagaraja V; Lacroix-Desmazes S; Kaveri SV
    Immunol Lett; 2007 May; 110(1):23-8. PubMed ID: 17467813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown.
    Abdi A; Linari S; Pieri L; Voorberg J; Fijnvandraat K; Castaman G
    Semin Thromb Hemost; 2018 Sep; 44(6):568-577. PubMed ID: 29439277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunobiology of inhibitor development in hemophilia A.
    Fijnvandraat K; Bril WS; Voorberg J
    Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
    Gouw SC; van den Berg HM; Fischer K; Auerswald G; Carcao M; Chalmers E; Chambost H; Kurnik K; Liesner R; Petrini P; Platokouki H; Altisent C; Oldenburg J; Nolan B; Garrido RP; Mancuso ME; Rafowicz A; Williams M; Clausen N; Middelburg RA; Ljung R; van der Bom JG;
    Blood; 2013 May; 121(20):4046-55. PubMed ID: 23553768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a.
    Gouw SC; Fijnvandraat K
    Semin Thromb Hemost; 2013 Oct; 39(7):740-51. PubMed ID: 24014072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A- A Systematic Review and Meta-Analysis.
    Abdi A; Bordbar MR; Hassan S; Rosendaal FR; van der Bom JG; Voorberg J; Fijnvandraat K; Gouw SC
    Front Immunol; 2020; 11():563. PubMed ID: 32457734
    [No Abstract]   [Full Text] [Related]  

  • 17. New predictive approaches for ITI treatment.
    Minno GD; Santagostino E; Pratt K; Königs C
    Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
    Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
    Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy.
    Robbins D; Kulkarni R; Gera R; Scott-Emuakpor AB; Bosma K; Penner JA
    Am J Hematol; 2001 Nov; 68(3):184-8. PubMed ID: 11754400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.